All subcategories » Health Technology Assessment Report
Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.
HTA - Health Technology Assessment Report
Details- 2014
- Whiting P
Dornase alfa for patients with cystic fibrosis: a review of the clinical efficacy and cost-effectiveness (Structured abstract)
HTA - Health Technology Assessment Report
Details- 2013
- CADTH
Inhaled tobramycin versus intravenous tobramycin for patients with cystic fibrosis: a review of the clinical effectiveness, cost effectiveness, and guidelines (Structured abstract)
HTA - Health Technology Assessment Report
Details- 2013
- CADTH
Mannitol for the treatment of cystic fibrosis in adults aged 18 years and above as an add-on therapy to best standard of care
HTA - Health Technology Assessment Report
Details- 2013
- Catalan Agency for Health Information, Assessment and Quality (CAHIAQ) - formerly CAHTA
Inhalation tobramycin for the management of cystic fibrosis (Structured abstract)
HTA - Health Technology Assessment Report
Details- 2013
- Pichon Riviere A
Newborn screening for cystic fibrosis: a review of the clinical and cost-effectiveness.
HTA - Health Technology Assessment Report
Details- 2012
- CADTH
Sodium chloride inhalation for the treatment of cystic fibrosis: a review of the clinical evidence, cost-effectiveness and guidelines.
HTA - Health Technology Assessment Report
Details- 2012
- CADTH
High frequency chest compression for ambulatory pulmonary physical therapy in patients with cystic fibrosis (Structured abstract)
HTA - Health Technology Assessment Report
Details- 2012
- Pichon Riviere A
eFlow® vibrating membrane nebulizer for the treatment of cystic fibrosis (Structured abstract)
HTA - Health Technology Assessment Report
Details- 2012
- Pichon Riviere A
Mannitol dry powder for inhalation for the treatment of cystic fibrosis
HTA - Health Technology Assessment Report
Details- 2011
- Health Technology Assessment